Stifel Reiterates Buy Rating, $36 Price Target on Athira Pharma (ATHA) Ahead of ATH-1017 Readout
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $36.00 price target on Athira Pharma (NASDAQ: ATHA), ahead of the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
